Founder exits board for senior management role; Hitesh Windlass becomes chairman

Key managerial personnel resignedManagement Changes View source PDF Explain this filing

WINDLAS · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+8.7%Reaction day

₹918.00

prior close

₹914.00

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is usedpendingvs market: pending

Pharmaceuticals peers, median of 173sector-0.3%+9.0% vs sector

On the reaction day the stock moved 9.0 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+6.6

10m

+6.9

15m

+10.4

30m

+10.2

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+8.7pendingpending-0.3+9.0

Next day

—————

15d

—————

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 173Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Windlas Biotech's unaudited September 2026 quarter revenue was Rs 2,639.08 million and profit Rs 180.52 million; half-year revenue was Rs 5,120.07 million and profit Rs 357.05 million. Founder Ashok Kumar Windlass resigned as whole-time director on November 5 and will, subject to shareholder approval, become Founder President from November 6 at Rs 15.6 million a year. Managing Director and promoter Hitesh Windlass became chairman.

Likely market impact

Succession continuity is the main positive, but Hitesh's added chair role concentrates leadership; Ashok's new post still needs shareholder approval.